BioGaia AB Interim Management Statement - January – March 2022
FIRST QUARTER 2022 Net sales amounted to SEK 283.9 million (202.0), an increase of SEK 81.9 million, or 41% (excluding foreign exchange effects, 32%) of which the acquisition of Nutraceutics accounted for an increase of SEK 15.8 million (8%). Organic growth was 24%. Net sales in the Paediatrics segment amounted to SEK 222.5 million (161.6), an increase of 38% (excluding foreign exchange effects, 29%). Net sales in the Adult Health segment amounted to SEK 60.8 million (38.7), an increase of 57% (excluding foreign exchange effects, 47%). Operating expenses amounted to SEK 106.9